Drugs / TritanrixHepB/Hib
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02207816 Background | Sep 2014 → Jan 2017 | malaria | GlaxoSmithKline | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TritanrixHepB/Hib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02207816 ↗ |
| Modality | Vaccine | “TritanrixHepB/Hib (MALARIA-055 PRI)” NCT02207816 ↗ |